X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.globenewswire.com//news-release/2023/10/31/2769844/0/en/Sosei-Heptares-Announces-Submission-of-New-Drug-Application-in-Japan-for-Daridorexant-ACT-541468-a-Dual-Orexin-Receptor-Antagonist-for-the-Treatment-of-Insomnia.html
https://www.prnewswire.com/news-releases/idorsia-announces-its-insomnia-medication-quviviq-daridorexant-is-now-covered-by-cvs-301872158.html
https://www.globenewswire.com/news-release/2023/06/12/2685940/0/en/Idorsia-launches-QUVIVIQ-daridorexant-in-Switzerland-a-first-in-class-treatment-for-chronic-insomnia-disorder-to-improve-both-nighttime-symptoms-and-daytime-functioning.html
https://endpts.com/idorsia-announces-few-details-on-potential-440-8m-asia-licensing-deal/
https://www.fiercepharma.com/pharma/idorsias-insomnia-drug-quviviq-be-investigated-dod-study-treatment-ptsd
https://www.prnewswire.com/news-releases/idorsia-pharmaceuticals-announces-support-for-a-clinical-trial-being-conducted-by-the-us-department-of-defense-evaluating-quviviq-daridorexant-as-potential-therapy-for-treatment-of-posttraumatic-stress-disorder-ptsd-301820179.html
https://www.globenewswire.com/news-release/2023/05/03/2659951/0/en/Health-Canada-approves-QUVIVIQ-daridorexant-for-the-management-of-adult-patients-with-insomnia.html
https://www.fiercepharma.com/pharma/idorsia-petitions-dea-get-its-insomnia-drug-quviviq-and-others-dora-class-controlled
https://www.fiercepharma.com/special-reports/2022-drug-approvals-after-aduhelm-fiasco-fda-endorsements-were-harder-come
https://www.globenewswire.com//news-release/2022/12/12/2571489/0/en/Long-term-safety-and-tolerability-results-with-daridorexant-in-patients-with-insomnia-disorder-published-in-CNS-Drugs.html
https://www.globenewswire.com//news-release/2022/12/12/2571490/0/en/Ad-hoc-announcement-pursuant-to-Art-53-LR-Roche-Changes-in-the-Board-of-Directors-and-the-Corporate-Executive-Committee.html
https://www.globenewswire.com/news-release/2022/12/05/2567025/0/en/Swissmedic-approves-QUVIVIQ-daridorexant-a-first-in-class-treatment-for-chronic-insomnia-disorder-to-improve-both-nighttime-symptoms-and-daytime-functioning.html
https://www.fiercepharma.com/marketing/idorsia-backed-sleep-survey-finds-sleeping-troubles-impacting-relationships
https://www.globenewswire.com/news-release/2022/11/15/2555647/0/en/QUVIVIQ-daridorexant-Europe-s-first-dual-orexin-receptor-antagonist-is-now-available-for-patients-with-chronic-insomnia-disorder-in-Italy-and-Germany.html
https://www.ema.europa.eu/en/documents/overview/quviviq-epar-medicine-overview_en.pdf
https://www.globenewswire.com/news-release/2022/10/03/2526462/0/en/Idorsia-Japan-announces-positive-results-with-daridorexant-in-a-Phase-3-study-of-Japanese-patients-with-insomnia.html
https://www.ema.europa.eu/en/documents/overview/quviviq-epar-medicine-overview_en.pdf
https://www.prnewswire.com/news-releases/idorsia-us-announces-first-wave-of-patients-prescribed-quviviq-daridorexant-through-partnership-with-pharmacy-services-provider-301547251.html
https://www.prnewswire.com/news-releases/idorsias-new-treatment-quviviq-daridorexant-is-now-available-in-the-us-for-adults-living-with-insomnia-301536832.html
https://www.pharmatimes.com/news/chmp_recommends_idorsias_dual_acting_treatment_quviviq_for_insomnia_patients_1388283
https://www.globenewswire.com/news-release/2022/02/25/2392060/0/de/QUVIVIQ-daridorexant-recommended-for-approval-in-Europe-as-a-new-treatment-for-adults-with-insomnia-disorder.html
https://www.globenewswire.com/news-release/2022/01/26/2373143/0/en/Idorsia-expands-its-commercialization-partnership-with-Syneos-Health-for-daridorexant-in-Europe-and-Canada.html
https://www.globenewswire.com/news-release/2022/01/20/2369791/0/en/The-Lancet-Neurology-reports-impact-of-daridorexant-on-both-nighttime-symptoms-and-daytime-functioning-in-adults-with-insomnia.html
https://endpts.com/fda-approves-potential-blockbuster-insomnia-drug-a-first-for-swiss-biotech-idorsia/
https://www.globenewswire.com/news-release/2021/03/10/2190042/0/en/FDA-accepts-the-new-drug-application-for-review-of-Idorsia-s-daridorexant-for-the-treatment-of-adult-patients-with-insomnia.html
http://www.pharmatimes.com/news/idorsia_submits_investigational_insomnia_treatment_daridorexant_to_the_ema_1364503
http://www.pharmatimes.com/news/idorsia_submits_investigational_insomnia_treatment_daridorexant_to_the_ema_1364503
https://www.globenewswire.com/news-release/2020/10/08/2105295/0/en/Idorsia-announces-capital-increase-to-prepare-for-the-launch-of-daridorexant-and-further-fund-its-diversified-pipeline.html
https://www.globenewswire.com/news-release/2020/08/28/2085631/0/en/Daridorexant-Phase-3-results-in-insomnia-presented-at-SLEEP-2020.html
https://www.globenewswire.com/news-release/2020/08/13/2077597/0/en/Daridorexant-Phase-3-results-in-insomnia-to-be-presented-at-SLEEP-2020.html
https://www.globenewswire.com/news-release/2020/08/06/2073859/0/en/Idorsia-Japan-confirms-daridorexant-dose-response-in-Japanese-patients-with-insomnia-preparation-for-a-local-registration-program-advancing.html
Market Place
Share 
